Malaria is a life-threatening disease caused by parasites and transmitted to humans via mosquitoes. Every year around a half million people die from malaria, many of whom are children under 5 years of age, and annually about 200 million people suffer from the disease worldwide.
After several years of development, a malaria vaccine (RS,S) was approved, however results have showed only about 50% efficacy. Therefore, there remains a pressing need for an effective malaria vaccine, and back in 2015, the WHO set an ambitious goal of 75% efficacy.
Recently, in a collaboration between the University of Oxford and Novavax, an adjuvanted R21 vaccine demonstrated an efficacy of 77% in a Phase 2 clinical trial – making it the first vaccine to meet the WHO goal and showing that the possibility of controlling malaria may finally be within reach.
Interestingly, the R21 clinical trial used the same adjuvant as Novavax’s COVID-19 vaccine, which was recently approved by the European Medicines Agency (EMA). An adjuvant is a potent component of a vaccine that stimulates the immune system and augments immune responses. Furthermore, Novavax’s adjuvant, called Matrix-M, was originally developed in Uppsala, Sweden and the company has several other Matrix-M adjuvanted vaccines in the pipeline including influenza, RSV, and Ebola.
Indeed, the road to a malaria vaccine has been a long uphill battle but the recent developments in new technologies offer the real possibility of saving millions of lives in the years to come.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
This cookie is installed by Google Analytics.
A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.